Wits partners with Biovac to bolster vaccine production

Director of the antiviral gene therapy research unit at Wits, Professor Patrick Arbuthnot spoke with eNCA's Jane Dutton. Courtesy of #DStv403

JOHANNESBURG - Wits University has teamed up with the pharmaceutical company Biovac to reinforce the country's vaccine production capabilities.

The collaboration will see viral-vectored vaccines being produced in South Africa.

READ: Biovac confident in ability to store and distribute vaccine

These vaccine types use the body' cells to develop antibodies to fight the virus. 

Patrick Arbuthnot said: "Basically the way it is working is that we have got expertise. We have got experience in making in making these engineer viruses. This is quite a specialised technology.

"I don’t think many other people in SA work on this. What we are doing is we transfer technology to Biovac so that they will have the capability to produce this engineered virus...once they have this they will incorporate these to their production facilities ..hopeful produce vaccine for SA and for African population ...efficiently and more cheaply."


Paid Content